Would you trust artificial intelligence (AI) enough to consume a drug made by it? Researchers at Oxford-based biotech company -- Exscientia -- have reportedly used AI tools to create a drug that is now ready to enter clinical human trials.
According to Engadget, the drug, known as DSP-1181, has been created using algorithms that scanned through compounds and checked against the database of parameters such as patient's genetic factors.
The drug is intended to treat obsessive-compulsive disorder and the clinical human trials begin in March.
AI has proven its efficiency in the early diagnosis of certain illnesses. It remains to be seen if patients or medical professionals will be comfortable prescribing something made entirely by a machine.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app